GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indo-Bangla Pharmaceuticals Ltd (DHA:IBP) » Definitions » Debt-to-EBITDA

Indo-Bangla Pharmaceuticals (DHA:IBP) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2018. Start your Free Trial

What is Indo-Bangla Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Indo-Bangla Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Indo-Bangla Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Indo-Bangla Pharmaceuticals's annualized EBITDA for the quarter that ended in . 20 was BDT0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Indo-Bangla Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

DHA:IBP's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Indo-Bangla Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Indo-Bangla Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indo-Bangla Pharmaceuticals Debt-to-EBITDA Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
Debt-to-EBITDA

Indo-Bangla Pharmaceuticals Semi-Annual Data
Debt-to-EBITDA

Competitive Comparison of Indo-Bangla Pharmaceuticals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indo-Bangla Pharmaceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Indo-Bangla Pharmaceuticals's Debt-to-EBITDA falls into.



Indo-Bangla Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Indo-Bangla Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Indo-Bangla Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.


Indo-Bangla Pharmaceuticals  (DHA:IBP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Indo-Bangla Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Indo-Bangla Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Plot No. 183, 6th Floor, Block B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in manufacturing, marketing and distribution of generic pharmaceuticals products which includes human drugs dosages form such as tablet, capsule, syrup, oral saline, suspension. The products of the company are sold in domestic market. The company has also applied for permission for production and selling of veterinary medicine.